Dr. Yuichi Wakabayashi, founder and medical directorEstablished in 2025 and headquartered in Osaka’s Shinsaibashi district, CELL GRAND CLINIC operates on a single principle in regenerative medicine: continuity of physician oversight from first inquiry through final follow-up.
Dr. Yuichi Wakabayashi, MD, PhD, founder and medical director, has treated over 3,000 patients across approximately 20 countries. The clinic operates under Japan’s Act on the Safety of Regenerative Medicine, with thirteen protocols carrying MHLW certification across Type II and Type III risk categories, and is accredited by Medical Excellence JAPAN (MEJ) for cross-border clinical care.
A Four-Stage Pathway without Clinical Delegation
How does the clinic structure treatment before patients travel to Osaka?
The patient journey unfolds across four structured stages. Before any travel commitment, Dr. Wakabayashi personally reviews each case, conducts a video consultation in English without an interpreter intermediating clinical content, and prepares a treatment plan with transparent outcome expectations.
“One physician designs the protocol, performs the procedure, and reviews the longitudinal outcome. Each cell product is cultured for one patient and is never pooled,” says Dr. Wakabayashi.
On the first visit in Osaka, patients undergo an in-person evaluation followed by minor fat harvesting under local anesthesia. During the cultivation interval, selected patients receive exosome or platelet-rich plasma therapy to address active symptoms while autologous cells are prepared. Harvested adipose-derived stem cells (ADSCs) are individually cultured at a GMP-compliant facility under continuous cleanroom monitoring and intentionally halted at passage three (P3), where proliferation potential and surface marker stability are optimally balanced.
Why is cell quality standardized before final clinical release decisions?
Final release requires FACS analysis confirming near-100 percent positivity for CD73, CD90 and CD105 under ISCT criteria, alongside cell viability of at least 95 percent. No batch pooling is performed.
Patients then return for personalized cell infusion, followed by structured one-, three- and six-month follow-ups conducted directly with Dr. Wakabayashi via video consultation, email and direct messaging between reviews.
The clinic’s highest-volume indications include musculoskeletal degeneration and chronic pain, endocrine and metabolic disease, vascular and post-event recovery and aesthetic and quality-of-life indications, including androgenetic alopecia, erectile dysfunction and systemic anti-aging programs.
-
One physician designs the protocol, performs the procedure, and reviews the longitudinal outcome. Each cell product is cultured for one patient and is never pooled.
The most consistently observed outcomes cluster around knee osteoarthritis, with measurable VAS and WOMAC improvement within 8 to 12 weeks, diabetes mellitus Type 1 and Type 2, where HbA1c reduction and insulin dose reduction are documented in selected cases, and AGA, with trichoscopy-confirmed follicular reactivation within approximately eight weeks.
A representative case involved a 60-year-old female with bilateral knee osteoarthritis, Kellgren-Lawrence grade III in the right knee and grade IV in the left. Six months after intra-articular autologous ADSC therapy, pain scores declined from 7-8/10 to 1/10 bilaterally, accompanied by restored mobility, imaging-confirmed cartilage improvement and resolution of secondary depressive symptoms as functional independence returned.
Managing Variability through Structural Choices
In what way does CELL GRAND CLINIC measure patient improvement?
Three challenges shape delivery at scale: variability in cell product quality, patient selection and outcome variability and discontinuity of care for international patients. These are addressed through product-level P3 standardization with ISCT verification, indication-specific candidacy assessment with expectations quantified in advance, and a fixed follow-up cadence supplemented by email and direct messaging so patients can reach the treating physician between sessions. Real improvement is defined as the convergence of three signals: a measurable change in indication-specific instruments, corroborating patient-reported function, and an imaging or laboratory change consistent with the proposed biological mechanism.
Environment, Evidence and Physician Commitment
Treatment plans are calibrated patient by patient against current peer-reviewed literature. The Shinsaibashi facility offers fully private consultation and treatment rooms, infusion suites for up to four patients, on-site Mandarin and Cantonese support alongside physician-level English, and Halal-compatible dining nearby. Dr. Wakabayashi has himself received stem cell and exosome therapy, prescribing only what he is willing to undergo, a standard the clinic submits openly as a useful test for any patient evaluating a regenerative offering across borders.
